| Substance | Condition | Seq | Src | PMID | Dtl | Title |
| Rapamycin | Acute Myeloid Leukemia | 2 | PM | 37588187 | 📋 | Overcoming adaptive resistance in AML by synergistically targeting FOXO3A-GNG7-mTOR axis with FOXO3A inhibitor Gardenoside and rapamycin |
| Rapamycin | Acute Myeloid Leukemia | 1 | PM | 35901982 | 📋 | Rapamycin inhibits the progression of human acute myeloid leukemia by regulating circ_0094100/miR-217/ATP1B1 axis |
| Rapamycin | Bladder Cancer | 1 | PM | 35783514 | 📋 | Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells |
| Rapamycin | Bone Cancer | 1 | PM | 36280393 | 📋 | Rapamycin-induced autophagy in osteosarcoma cells is mediated via the biglycan/Wnt/β-catenin signaling axis |
| Rapamycin | Breast Cancer | 5 | PM | 37787375 | 📋 | A systems biology approach and in vitro experiment indicated Rapamycin targets key cancer and cell cycle-related genes and miRNAs in triple-negative breast cancer cells |
| Rapamycin | Breast Cancer | 4 | PM | 37225011 | 📋 | Combination therapy with PD-1 inhibition plus rapamycin and metformin enhances anti-tumor efficacy in triple negative breast cancer |
| Rapamycin | Breast Cancer | 3 | PM | 36152730 | 📋 | Histone deacetylase inhibitor panobinostat in combination with rapamycin confers enhanced efficacy against triple-negative breast cancer |
| Rapamycin | Breast Cancer | 2 | PM | 36063263 | 📋 | Comparison of dual mTORC1/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of breast cancer cells using proton nuclear magnetic resonance spectroscopy metabolomics |
| Rapamycin | Breast Cancer | 1 | PM | 35822679 | 📋 | Immunosuppressive Effects and Potent Anti-tumor Efficacy of mTOR Inhibitor Everolimus in Breast Tumor-bearing Mice |
| Rapamycin | Cancer | 6 | PM | 37240915 | 📋 | Three Layers of Personalized Medicine in the Use of Sirolimus and Its Derivatives for the Treatment of Cancer |
| Rapamycin | Cancer | 5 | PM | 37057884 | 📋 | Cancer prevention with rapamycin |
| Rapamycin | Cancer | 4 | PM | 37049920 | 📋 | Targeting mTOR for Anti-Aging and Anti-Cancer Therapy |
| Rapamycin | Cancer | 3 | PM | 36109789 | 📋 | Recent advances and limitations of mTOR inhibitors in the treatment of cancer |
| Rapamycin | Cancer | 2 | PM | 36073856 | 📋 | Long-term treatment with low dose rapamycin extends lifespan and delays tumours in cancer-prone germline PTEN mutant mice |
| Rapamycin | Cancer | 1 | PM | 35973640 | 📋 | Immunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention |
| Rapamycin | Cisplatin Toxicity | 1 | PM | 36248001 | 📋 | Alleviation of cisplatin-induced neuropathic pain, neuronal apoptosis, and systemic inflammation in mice by rapamycin |
| Rapamycin | Colon Cancer | 2 | PM | 36063298 | 📋 | Rapamycin Enhanced Sensitivity of HT-29 Cells to 5-Fluororacil by Promoting Autophagy |
| Rapamycin | Colon Cancer | 1 | PM | 15612989 | 📋 | Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer |
| Rapamycin | Colorectal Cancer | 2 | PM | 36325149 | 📋 | Rapamycin Liposomes Combined with 5-Fluorouracil Inhibits Angiogenesis and Tumor Growth of APC (Min/+) Mice and AOM/DSS-Induced Colorectal Cancer Mice |
| Rapamycin | Colorectal Cancer | 1 | PM | 35731713 | 📋 | Combination of mTOR inhibitor PP242 and AMPK activator metformin exerts enhanced inhibitory effects on colorectal carcinoma cells in vitro by blocking multiple kinase pathways |
| Rapamycin | Leukemia | 1 | PM | 38530586 | 📋 | Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mTORC1 pathway-mediated apoptosis and autophagy |
| Rapamycin | Liposarcoma | 2 | PM | 37400145 | 📋 | Targeting Autophagy With the Synergistic Combination of Chloroquine and Rapamycin as a Novel Effective Treatment for Well-differentiated Liposarcoma |
| Rapamycin | Liposarcoma | 1 | PM | 36309387 | 📋 | Chloroquine Combined With Rapamycin Arrests Tumor Growth in a Patient-derived Orthotopic Xenograft (PDOX) Mouse Model of Dedifferentiated Liposarcoma |
| Rapamycin | Liver Cancer | 3 | PM | 36513566 | 📋 | Sirolimus improves the prognosis of liver recipients with hepatocellular carcinoma: A single-center experience |
| Rapamycin | Liver Cancer | 2 | PM | 36303309 | 📋 | Antitumor Effect of Low-Dose of Rapamycin in a Transgenic Mouse Model of Liver Cancer |
| Rapamycin | Liver Cancer | 1 | PM | 35977851 | 📋 | Sirolimus Attenuates Calcineurin Inhibitor-Induced Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma |
| Rapamycin | Liver Cancer | 4 | PM | 24325131 | 📋 | Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma |
| Rapamycin | Melanoma | 1 | PM | 38385108 | 📋 | Rapamycin inhibits B16 melanoma cell viability invitro and invivo by inducing autophagy and inhibiting the mTOR/p70‑S6k pathway |
| Rapamycin | Neuroblastoma | 2 | PM | 37370314 | 📋 | Effects of Monensin and Rapamycin Combination Therapy on Tumor Growth and Apoptosis in a Xenograft Mouse Model of Neuroblastoma |
| Rapamycin | Neuroblastoma | 1 | PM | 36978413 | 📋 | Monensin, an Antibiotic Isolated from Streptomyces Cinnamonensis, Regulates Human Neuroblastoma Cell Proliferation via the PI3K/AKT Signaling Pathway and Acts Synergistically with Rapamycin |
| Rapamycin | Oral Cancer | 2 | PM | 38276004 | 📋 | Rapamycin as a Potential Alternative Drug for Squamous Cell Gingiva Carcinoma (Ca9-22): A Focus on Cell Cycle, Apoptosis and Autophagy Genetic Profile |
| Rapamycin | Oral Cancer | 1 | PM | 36185289 | 📋 | Rapamycin inhibits oral cancer cell growth by promoting oxidative stress and suppressing ERK1/2, NF-κB and beta-catenin pathways |
| Rapamycin | Pancreatic Cancer | 1 | PM | 29434877 | 📋 | Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo |
| Rapamycin | T-Cell Leukemia | 1 | PM | 33300153 | 📋 | Growth inhibition and suppression of the mTOR and Wnt/β-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and MYCN depletion |
| Rapamycin | Testicular Cancer | 1 | PM | 36598515 | 📋 | Effect of rapamycin treatment in human seminoma TCam-2 cells through inhibition of G1-S transition |
